Spyre Therapeutics
Spyre Therapeutics is dedicated to developing next-generation therapeutics for inflammatory bowel disease (IBD) and other immune-mediated diseases. Their mission is to improve treatment options by creating potential best-in-class antibodies, rational therapeutic combinations, and precision immunology approaches with a focus on efficacy and convenience. The company aims to address unmet needs in IBD care, including response durability, safety, and adherence, by leveraging innovative scientific research and a collaborative environment.
Industries
Nr. of Employees
small (1-50)
Products
Pipeline of monoclonal antibody candidates for inflammatory bowel disease
A portfolio of monoclonal antibody therapeutic candidates in preclinical and development-stage programs focused on treating inflammatory bowel disease (ulcerative colitis and Crohn’s disease).
Pipeline of monoclonal antibody candidates for inflammatory bowel disease
A portfolio of monoclonal antibody therapeutic candidates in preclinical and development-stage programs focused on treating inflammatory bowel disease (ulcerative colitis and Crohn’s disease).
Services
Preclinical characterization, DMPK studies, PK modeling, bioanalysis and GLP toxicology to support IND-enabling packages.
End-to-end clinical development capabilities including protocol design, global clinical operations, translational integration and late-stage program management.
CMC development, manufacturing operations oversight, and supply chain management for clinical and commercial biologics.
Regulatory planning and management of interactions with health authorities to support clinical development and marketing applications.
IP management, patent prosecution and strategic IP counseling for biologics and discovery assets.
Business development, licensing, partnership formation and corporate strategy to advance pipeline assets and transactions.
Preclinical characterization, DMPK studies, PK modeling, bioanalysis and GLP toxicology to support IND-enabling packages.
End-to-end clinical development capabilities including protocol design, global clinical operations, translational integration and late-stage program management.
CMC development, manufacturing operations oversight, and supply chain management for clinical and commercial biologics.
Regulatory planning and management of interactions with health authorities to support clinical development and marketing applications.
IP management, patent prosecution and strategic IP counseling for biologics and discovery assets.
Business development, licensing, partnership formation and corporate strategy to advance pipeline assets and transactions.
Expertise Areas
- Monoclonal antibody development
- Precision immunology and combination strategies
- Preclinical DMPK and safety assessment
- Clinical trial design and management
Key Technologies
- Monoclonal antibody therapeutics
- Drug metabolism and pharmacokinetic modeling
- GLP toxicology testing
- Bioanalytical assays